ArticleScience translational medicine2020

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

Florence Coussy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.